XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis
Authors:
- Nikos ManiadakisNMNikos Maniadakis
- Vasilios FragoulakisVFVasilios Fragoulakis
- Dimitrios PectasidesDPDimitrios Pectasides
- George FountzilasGFGeorge Fountzilas
- 15 January 2009
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 25 (3) , 797-805
Abstract
An economic analysis (based on interim data from a long-term, randomised, multi-centre, controlled, clinical trial) to evaluate chemotherapy with XELOX (capecitabine/oxaliplatin) versus FOLFOX6 (5Fluorouracil/leucovorin/oxaliplatin) as an adjuvant treatment for high risk colorectal cancer patients in Greece.As survival rate was the same in the two arms, a cost-minimisation analysis was carried out, from the perspectives of the National Health Service (NHS), Social Insurance Funds (SIF) and patients in Greece. Patient data were combined with 2008 unit prices to estimate the total cost of patient care, the patients' travelling expenditure and their productivity losses. Raw data were bootstrapped 5000 times in order to allow statistical testing.From an NHS perspective, the mean chemotherapy cost was 8762 euro with FOLFOX6 and 9713 euro with XELOX; costs of administration and hospitalisations were 5154 euro and 1050 euro, respectively. Total treatment cost with FOLFOX6 reached 17,480 euro and with XELOX 12 525 euro, a difference of 4955 euro (p < 0.001) in favour of the latter therapy. From an SIF perspective, the total cost of treatment was 16,240 euro with FOLFOX6 and 12,617 euro with XELOX, a reduction of 3623 euro (p < 0.001) with the latter therapy. Mean patient travelling cost was 184 euro with FOLFOX6 and 80 euro with XELOX, a difference of 104 euro (p < 0.001). Mean productivity loss was 100 euro with FOLFOX6 and 31 euro with XELOX, a difference of 69 euro (p < 0.001).Chemotherapy combining oral capecitabine and oxaliplatin reduces total treatment cost for the Greek National Health Service and Social Insurance Funds, mainly through a reduction in the cost of administration. From patients' perspective, it reduces travelling expenditure and productivity losses. Therefore, this combination may be a cost-effective approach for the management of colorectal cancer patients who have had surgery in Greece. This is an analysis alongside a clinical trial, and should be interpreted in this specific context in which it was undertaken.Keywords
This publication has 43 references indexed in Scilit:
- Pharmacoeconomic Benefits of Capecitabine-Based Chemotherapy in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in GreeceLung Cancer, 2007
- Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in GreeceCurrent Medical Research and Opinion, 2007
- Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French SettingOncology, 2007
- Cost Considerations in the Treatment of Colorectal CancerPharmacoEconomics, 2007
- Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancerBritish Journal of Cancer, 2006
- Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialBritish Journal of Cancer, 2006
- Costs of treatment of colorectal cancer in different settings in GermanyThe European Journal of Health Economics, 2004
- Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UKThe European Journal of Health Economics, 2003
- Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorinEuropean Journal of Cancer, 2002